Drug development - August 15, 2016
A simplified approach to drug development discovered
For the first time, researchers have revealed the nanostructure of the mesoporous magnesium carbonate Upsalite and pore size control was achieved without organic templates or swelling agents. By controlling the pore structure of the material the amorphous phase stabilisation exerted on poorly soluble drug compounds can be tuned and the drug delivery rate can be […]
Drug development - August 12, 2016
PCI Biotech receives positive opinion from EMA
PCI Biotech has announced that it has received a positive opinion from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) for its lead product candidate, fimaporfin, for the treatment of cholangiocarcinoma (bile duct cancer). COMP’s positive opinion is subject to decision by the European Commission for Orphan Designation. Fimaporfin (AmphinexTM) is in clinical […]
Drug development - September 8, 2014
BerGenBio granted platform patent
The Norwegian oncology biopharmaceutical company has announced that the United States Patent and Trademark Office (USPTO) has issued United States Patent 8,735,064 covering a method for creating and identifying functional interference RNA (RNAi) molecules. RNAis are recombinant nucleic acid molecules that have the ability to specifically down-regulate an expressed target gene in vivo. This patent protects BerGenBio’s CellSelect(TM) platform technology […]
Drug development - April 3, 2014
Novozymes to open new R&D center in the US
Novozymes has announced the establishment of a new research and development center in the US dedicated to its bioagriculture business. The center will be located near the Research Triangle Park in Cary, North Carolina where the company will, according to Novozymes, invest $36 million over the next three years and create 100 new research and […]
Drug development - January 23, 2014
Kancera starts ROR study
The company has announced that it is initiating the development of a vaccine directed against ROR. Kancera’s strategy is, according to the Karolinska Institutet Science Park company, to use its future small-molecule ROR inhibitors as a first line treatment for the disease and thereafter follow with a prophylactic ROR vaccine to prevent relapse. The initiative is motivated by […]
Drug development - August 16, 2013
Genovis evaluates new diagnosis technology
Genovis has signed an agreement with Respiratorius to evaluate a new technology for the early diagnosis of cardiovascular disease. The agreement involves tests and evaluation of RESP-3000 as a new biomarker for early diagnosis of cardiovascular disease using PET-imaging. The final evaluation will be conducted by GeccoDots AB, Genovis’ wholly owned subsidiary. According to a […]
